CEACAM8

CEACAM8 (CD66b/CGM6/NCA-95) is a GPI-anchored, granulocyte-specific glycoprotein that functions both as a surface activation receptor on neutrophils and eosinophils and as a secreted negative regulator of mucosal inflammation (PMID:1370882, PMID:18056392, PMID:24743304). It is a ~100 kDa glycoprotein released by PI-PLC, stored in gelatinase and specific granules of resting cells, and mobilized to the surface upon activation, where its expression is tightly restricted to the granulocyte lineage (PMID:1370882, PMID:10553088, PMID:9427723). Its N-terminal domain mediates carbohydrate-independent heterophilic adhesion to CEACAM6, through residues mapped by mutagenesis that overlap the CEACAM6 homophilic and Neisseria Opa binding sites (PMID:8645267, PMID:11590190). At the cell surface CEACAM8 resides in lipid rafts and constitutively associates with the β2 integrin CD11b; engagement by cross-linking antibody or its natural ligand galectin-3 activates the Src-family kinase Hck, drives D-mannose-sensitive clustering of CD11b, upregulates CD11/CD18, and triggers calcium-dependent adhesion, superoxide production, degranulation, and release of pre-stored IL-8 (PMID:8699114, PMID:10553088, PMID:18056392, PMID:17002897, PMID:10233903). In its soluble secreted form—released by granulocytes in response to bacterial DNA via TLR9 and to extracellular chromatin—CEACAM8 binds CEACAM1 on airway epithelium, inducing ITIM phosphorylation, SHP-1 recruitment, and suppression of TLR2-driven PI3K-Akt signaling (PMID:24743304, PMID:31258530).

1. 1992 High

   Establishing that CD66b is a GPI-anchored granulocyte surface glycoprotein defined the molecular nature of the protein and explained how it could be mobilized and shed.

   Evidence Immunoprecipitation, PI-PLC cleavage, and deglycosylation of granulocyte surface protein

   PMID:1370882

   Open questions at the time

   • Did not define signaling or adhesion function
   • No structural detail on the glycosylated ectodomain
2. 1996 Medium

   Demonstrating that antibody engagement of CD66b triggers calcium-dependent upregulation of CD11/CD18 and increased neutrophil adhesion showed the molecule transmits activating signals rather than acting as a passive marker.

   Evidence Functional adhesion assay, calcium chelation, and sequential desensitization with CD66 mAbs

   PMID:8699114

   Open questions at the time

   • Identity of the physiological ligand unknown at this stage
   • Downstream kinases not defined
3. 1996 High

   Reconstituting heterophilic adhesion with recombinant proteins established that CD66b binds CD66c (NCA) through N-terminal domains independently of carbohydrate, linking adhesion to functional superoxide output.

   Evidence Soluble recombinant protein binding, deglycosylation control, CHO transfectant adhesion, superoxide assay

   PMID:8645267

   Open questions at the time

   • Residues mediating adhesion not yet mapped
   • In vivo relevance of heterophilic adhesion untested
4. 1998 High

   Transgenic expression of a CGM6 cosmid showed the gene carries all elements for granulocyte-restricted expression, defining its lineage specificity and developmental onset.

   Evidence Transgenic mice with cosmid insert, Northern blot, immunohistochemistry, FACS of bone marrow/spleen

   PMID:9427723

   Open questions at the time

   • No loss-of-function phenotype examined
   • Regulatory elements not individually mapped
5. 1999 High

   Identifying CD66b as a major neutrophil galectin-3 receptor stored in granules connected the molecule to an endogenous lectin ligand and to regulated mobilization.

   Evidence Galectin-3-Sepharose affinity chromatography, subcellular granule fractionation, immunoblot, HL-60 differentiation

   PMID:10553088

   Open questions at the time

   • Functional consequence of galectin-3 binding not resolved here
   • Binding stoichiometry/affinity not quantified
6. 1999 Medium

   Showing lectin-like physical interaction with CD11b/CD18 and D-mannose-sensitive CD11b clustering, plus a requirement in antibody-dependent cytolysis, positioned CD66b as a functional partner of β2 integrins.

   Evidence Immunofluorescence redistribution, D-mannose inhibition, anti-CD66b mAb inhibition of cytolysis

   PMID:10233903

   Open questions at the time

   • Molecular basis of the lectin-like interaction undefined
   • Signaling intermediates not identified
7. 2001 High

   Mapping critical N-domain residues for CEACAM8–CEACAM6 heterophilic adhesion refined the binding interface and distinguished it from homophilic and pathogen-binding sites.

   Evidence Homologue-scanning mutagenesis, chimeric protein expression, CHO transfectant adhesion assay

   PMID:11590190

   Open questions at the time

   • No co-crystal structure of the interface
   • Physiological context of the adhesion not addressed
8. 2006 Medium

   Demonstrating that CD66b cross-linking releases pre-stored IL-8 without de novo synthesis distinguished its rapid-release signaling output from transcription-dependent cytokine responses.

   Evidence CD66b mAb cross-linking, IL-8 ELISA, comparison to LPS-driven synthesis

   PMID:17002897

   Open questions at the time

   • Storage compartment for IL-8 not defined
   • Signaling pathway from CD66b to release not mapped
9. 2007 High

   Assembling the surface signaling mechanism—lipid raft localization, constitutive CD11b association, galectin-3/mAb engagement activating Hck, and GPI/raft-dependent effector functions—integrated CD66b into a defined raft-based activation module on eosinophils.

   Evidence Co-IP, lipid raft fractionation, GPI removal, mAb cross-linking, superoxide and degranulation assays, confocal microscopy

   PMID:18056392

   Open questions at the time

   • How a GPI-anchored protein transmits signal across the membrane mechanistically unresolved
   • Relative roles of Hck versus other kinases unquantified
10. 2014 High

    Showing that soluble CEACAM8 binds epithelial CEACAM1 to drive ITIM phosphorylation, SHP-1 recruitment, and suppression of TLR2 PI3K-Akt signaling revealed an anti-inflammatory secreted function distinct from its surface activating role.

    Evidence Recombinant CEACAM8-Fc binding, ITIM phosphorylation, SHP-1 co-IP, PI3K-Akt readout, TLR9 dependency

    PMID:24743304

    Open questions at the time

    • In vivo demonstration of airway inflammation suppression not shown
    • Affinity of soluble CEACAM8 for CEACAM1 not quantified
11. 2019 Medium

    Identifying extracellular chromatin as a trigger for soluble CEACAM8 secretion via both neo-synthesis and degranulation clarified the stimulus and routes generating the anti-inflammatory soluble form.

    Evidence Primary PMN stimulation with chromatin/nucleosomes, CEACAM8 ELISA, degranulation and protein synthesis inhibition assays

    PMID:31258530

    Open questions at the time

    • Receptor sensing extracellular chromatin not defined
    • Relative contribution of synthesis versus degranulation in vivo unknown

• How CEACAM8's two functional modes—surface raft-based activation of granulocytes versus secreted CEACAM1-mediated immunosuppression—are coordinated in vivo, and the precise transmembrane signaling mechanism for a GPI-anchored receptor, remain unresolved.
• No structural model of CEACAM8 ectodomain or its complexes
• Balance of activating versus suppressive functions during infection untested in vivo
• Transmembrane signal transduction mechanism unresolved